文献速递乳腺病理细胞病理与分子病理

转移性三阴性乳腺癌PD-L1检测:CPS与IC评分的观察者间及平台间可重复性

PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
PubMed 文献 · Hum Pathol · 2024-01-24

本研究评估转移性三阴性乳腺癌(mTNBC)中PD-L1检测的观察者间和检测间可重复性。对60例样本使用22C3 pharmDx(Dako平台)和SP263(Ventana平台)评估CPS,其中19例子集用SP142评估IC。结果显示两种CPS检测的观察者内和观察者间一致性均高(ICC>0.9,Fleiss κ>0.9),IC评分观察者间完全一致。CPS与IC识别不同患者队列,不可互换。

要点

  • 22C3和SP263检测CPS在mTNBC中显示高度可重复性(ICC>0.9)。
  • SP142评估IC评分观察者间完全一致。
  • CPS(帕博利珠单抗阈值CPS≥10)与IC(阿替利珠单抗阈值IC≥1%)不可互换。

核心结论

  • 在mTNBC中,使用22C3 pharmDx或VENTANA SP263评估CPS均具有高度可靠性。
  • CPS和IC识别不同的患者队列,因此不可互换。

研究设计与样本

  • 回顾性评估60例mTNBC样本,使用22C3 pharmDx(Dako Autostainer Link 48)和VENTANA PD-L1 SP263(Ventana BenchMark Ultra)检测PD-L1。
  • 其中19例子集使用SP142(Ventana BenchMark Ultra)检测。
  • CPS由5名认证PD-L1培训师的病理学家独立评估;IC由其中3名乳腺病理专家评估。

主要发现

  • 22C3的CPS ICC为0.939(95%CI 0.913-0.96),SP263为0.972(95%CI 0.96-0.982),两者合并为0.909(95%CI 0.874-0.938),均p<0.001。
  • Fleiss κ显示22C3为0.938(95%CI 0.857-1.018),SP263为0.972(95%CI 0.890-1.052),合并为0.907(95%CI 0.869-0.945)。
  • IC评分观察者间达到完全一致。

关键数值与推荐

  • 帕博利珠单抗相关CPS阈值为CPS≥10。
  • 阿替利珠单抗相关IC阈值为IC≥1%。
  • 22C3 pharmDx必须在Dako平台使用,VENTANA SP263必须在Ventana平台使用。

临床怎么用

  • mTNBC的PD-L1检测可选择22C3 pharmDx或VENTANA SP263评估CPS,但需在各自指定平台进行。
  • CPS和IC评分分别对应不同的免疫检查点抑制剂,临床选择药物时应使用相应评分系统,不可互换。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PD-L1 test is recommended in different types of tumors to select patients eligible for immune checkpoint inhibitors (ICI) therapy. Several factors make this test challenging in metastatic triple-negative breast cancer (mTNBC). Different assays and platforms are available, each associated with distinct scoring systems and threshold values specific to the ICI compound used, i.e. CPS≥10 for pembrolizumab and IC ≥ 1 % for atezolizumab. Our objective was to assess the consistency of PD-L1 testing in mTNBC by examining interobserver and interassay reproducibility. We assessed n = 60 mTNBC samples for PD-L1 testing using 22C3 pharmDx assay on a Dako Autostainer Link 48 and VENTANA PD-L1 (SP263) on a Ventana BenchMark Ultra. Additionally, a subset of n = 19 samples was tested using the SP142 assay, also on the Ventana BenchMark Ultra. CPS with both 22C3 and SP263 was independently evaluated by five pathologists, all certified PD-L1 trainers. The IC with SP142 was assessed by three of these pathologists, who have particular expertise in breast pathology. Following the computation of the intraclass correlation coefficient (ICC) for each assay and their respective thresholds, we assessed the agreement between different raters and assays using Fleiss's κ, with a 95 % confidence interval (CI). Overall, we observed a significant (p < 0.001) ICC with both CPS assays [22C3 = 0.939 (CI:0.913-0.96); SP263 = 0.972 (CI:0.96-0.982); combined 22C3-SP263 = 0.909 (CI:0.874-0.938)]. Fleiss's κ confirmed an almost perfect agreement among pathologists and assays: 22C3 = 0.938 (CI:0.857-1.018); SP263 = 0.972 (CI:0.890-1.052); combined 22C3-SP263 = 0.907 (CI:0.869-0.945). Perfect inter-rater agreement was reached considering IC. This study establishes the reliability of assessing CPS in mTNBC using either the 22C3 pharmDx, as employed in the KEYNOTE studies, or the VENTANA SP263 assay. Each assay must be used on its designated platform, namely the Dako for 22C3 pharmDx and the Ventana for VENTANA SP263. It is important to remark that CPS and IC identify different patient cohorts and, therefore, are not interchangeable.

来源:Hum Pathol,查看原文。版权归原作者所有。

引用

  1. Ivanova M, Frascarelli C, Cerbelli B, et al. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores. Hum Pathol. 2024. PMID: 38278450. doi:10.1016/j.humpath.2024.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。